Monopar Therapeutics (NASDAQ:MNPR) Releases Earnings Results, Misses Estimates By $1.87 EPS

Monopar Therapeutics (NASDAQ:MNPR) announced its quarterly earnings data on Monday. The company reported ($2.23) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($1.87), Zacks reports.

Monopar Therapeutics Stock Down 8.2 %

Shares of Monopar Therapeutics stock traded down $2.98 during trading hours on Tuesday, hitting $33.43. The company’s stock had a trading volume of 36,875 shares, compared to its average volume of 51,198. The business has a fifty day moving average of $38.48 and a 200 day moving average of $24.33. Monopar Therapeutics has a 1-year low of $1.72 and a 1-year high of $54.30. The company has a market capitalization of $203.99 million, a PE ratio of -16.97 and a beta of 1.18.

Wall Street Analysts Forecast Growth

MNPR has been the topic of a number of research analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $76.00 price target on shares of Monopar Therapeutics in a report on Wednesday, March 19th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Monopar Therapeutics in a research note on Tuesday.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.